Best Longevity Peptides Being Studied
Best Longevity Peptides Being Studied in 2026
Longevity science is no longer concerned only with adding years to life. Modern geroscience increasingly asks whether the years of life spent in good physical, metabolic, immune, and cognitive condition can be extended. This period is commonly described as healthspan.
Peptides are of interest because many act as signaling molecules. Depending on the molecule and research model, peptide signals may be investigated in connection with mitochondrial communication, cellular stress responses, metabolic regulation, immune signaling, tissue remodeling, inflammation, and gene expression. However, the scientific maturity of these compounds varies widely. Some have been examined mainly in cells or animals, while others have entered human clinical development for defined medical conditions.
The most responsible way to discuss longevity peptides is therefore not to label them as anti-aging solutions, but to examine the biological questions researchers are testing, the methods used, the findings reported to date, and the limitations that remain.
What Longevity Researchers Are Trying to Understand
Why do some cells, tissues, and organs age faster than others?
Can biological aging be measured more accurately than chronological age?
How does mitochondrial decline contribute to impaired tissue function?
Can damaged mitochondria be repaired, replaced, or removed more efficiently?
Why do senescent cells accumulate with age, and when does senescence shift from helpful to harmful?
Can inflammatory signaling from senescent cells be reduced without disrupting normal wound repair or tumor-suppression functions?
Which biomarkers can show whether an intervention affects aging biology rather than only a short-term symptom?
The Major Biological Features of Aging
Genomic instability and accumulated DNA damage
Telomere attrition
Epigenetic alterations
Loss of proteostasis, including impaired protein folding and removal
Deregulated nutrient sensing
Mitochondrial dysfunction
Cellular senescence
Stem cell exhaustion
Altered communication between cells and tissues
Research note: Mitochondrial dysfunction and cellular senescence are widely discussed within hallmark-based frameworks of aging, but the pathways overlap. A single intervention may affect several systems, which makes causal interpretation difficult.
Leading Longevity Peptides Being Studied
MOTS-c is a mitochondrial-derived peptide encoded within mitochondrial DNA. Its discovery helped expand the view of mitochondria from energy-producing organelles to signaling structures capable of communicating metabolic and stress information to the rest of the cell.
Why researchers are interested
Metabolic homeostasis and nutrient-sensing pathways
AMP-activated protein kinase, commonly called AMPK, and cellular energy stress
Glucose utilization and metabolic flexibility in experimental models
Exercise-related signaling and adaptation
Communication between mitochondria and the nucleus
What has been found
Preclinical research has associated MOTS-c with metabolic regulation and cellular adaptation to energetic stress.
Research interest is strengthened by the observation that mitochondrial-derived peptides may function as signaling molecules rather than as simple by-products of mitochondrial activity.
Human relevance, optimal biomarkers, long-term effects, and clinical utility remain under investigation.
Key limitation
Mechanistic and preclinical findings should not be treated as proof of an anti-aging effect in humans.
Humanin
Humanin is another mitochondrial-derived peptide associated with cell-survival and stress-response research. It was identified through investigations of cellular protection and has since been studied in models involving oxidative stress, metabolism, protein homeostasis, and neurobiology.
Research questions
How does Humanin influence cellular stress resistance?
Does it modify apoptosis-related signaling under specific experimental conditions?
How do circulating or tissue Humanin levels change with age and disease state?
Can Humanin-related pathways reveal broader mechanisms of mitochondrial communication?
What has been found
Experimental studies support a role for Humanin in cellular stress-response networks.
Associations between Humanin biology and aging have generated interest, but associations do not establish that modifying Humanin will slow human aging.
More standardized human research is required to determine clinical relevance.
SS-31, also known as Elamipretide
SS-31 is a mitochondria-targeting synthetic peptide studied for its interaction with mitochondrial membranes and cellular bioenergetics. It differs from mitochondrial-derived peptides because it is designed to localize to mitochondria rather than being encoded by mitochondrial DNA.
Research focus
Mitochondrial membrane structure and function
Cardiolipin-related biology
Electron transport and ATP-generating efficiency
Oxidative stress and bioenergetic failure
Muscle, cardiovascular, ocular, and other disease-specific research models
What has been found
Preclinical studies support effects on mitochondrial structure and function in selected models.
Clinical development has explored defined medical conditions rather than generalized anti-aging use.
Results from one disease population cannot automatically be generalized to healthy aging or lifespan extension.
Epitalon, also called Epithalon
Epitalon is a synthetic tetrapeptide associated with research originating from pineal peptide and bioregulator programs. It is frequently discussed in relation to telomeres, circadian biology, oxidative stress, and age-related signaling.
Research focus
Telomerase and telomere-related cellular models
Circadian and pineal signaling
Oxidative and cellular stress pathways
Gene regulation and cellular aging models
What has been found
Laboratory findings have generated hypotheses about telomere biology and cellular aging.
The evidence base is heterogeneous, and study quality, replication, and translation to broad human longevity claims remain important limitations.
Telomere length alone is not a complete measurement of aging, and increasing telomerase activity is not automatically beneficial because cell-growth pathways require careful safety evaluation.
GHK-Cu is a naturally occurring copper-binding peptide widely known within skin, extracellular matrix, and tissue-remodeling research. Its relevance to longevity science comes from broader interest in repair capacity, inflammatory signaling, gene expression, and maintenance of tissue structure.
Research focus
Extracellular matrix remodeling
Collagen and tissue-repair pathways
Wound-healing models
Inflammatory signaling
Gene-expression patterns related to maintenance and repair
What has been found
Research supports biological activity in tissue-remodeling and skin-related models.
The leap from localized repair biology to whole-body longevity remains unproven.
Researchers still need clearly defined outcomes, standardized preparations, and stronger human evidence for broad aging claims.
Thymosin Alpha-1 is an immune-regulating peptide studied in relation to T-cell activity, innate and adaptive immune responses, and inflammatory balance. It is relevant to longevity research because age-related immune decline, often called immunosenescence, can alter infection response, vaccine response, cancer surveillance, and inflammatory regulation.
Research focus
T-cell maturation and immune signaling
Innate and adaptive immune coordination
Inflammatory balance
Immune dysfunction in defined disease settings
What has been found
The peptide has an established history of immune-focused research and regulated medical use in some jurisdictions and indications.
Immune modulation should not be described as general immune boosting. Immune systems require balance, and excessive activation may also be harmful.
Evidence from disease-specific use does not prove lifespan extension or generalized rejuvenation.
FOXO4-DRI
FOXO4-DRI is an experimental peptide designed around interactions involving FOXO4 and p53, two proteins relevant to cell-cycle control, stress responses, and apoptosis. It became prominent through preclinical senescence research examining whether selected senescent cells could be pushed toward programmed cell death.
What has been found
Early animal studies produced interest by reporting functional changes after targeting senescent cells in specific models.
The approach remains experimental, and the heterogeneity of senescent cells is a central challenge.
Selectivity, delivery, tissue effects, cancer biology, immune consequences, and long-term safety require extensive investigation.
Key limitation
FOXO4-DRI should not be presented as a proven human rejuvenation intervention. The evidence base is predominantly preclinical.
KPV is a three-amino-acid fragment associated with alpha-melanocyte-stimulating hormone biology. It is studied mainly for inflammatory signaling, epithelial barrier models, and gastrointestinal research rather than as a direct lifespan-extending peptide.
Research focus
Inflammatory signaling pathways
Epithelial and intestinal barrier function
Immune-cell communication
Laboratory models of localized inflammation
Longevity relevance
Chronic, low-grade inflammation is strongly connected with aging research, often described as inflammaging.
A peptide can be relevant to one feature of aging without being a comprehensive longevity intervention.
Human clinical evidence for generalized longevity outcomes remains limited.
Precision Aging Research
Precision aging research applies the logic of precision medicine to geroscience. Instead of assuming that everyone of the same chronological age has the same biology, researchers measure molecular, physiological, functional, environmental, and lifestyle differences to estimate how aging is occurring in a particular person, tissue, or organ.
Chronological age versus biological age
Chronological age measures time since birth.
Biological age attempts to describe accumulated molecular and physiological change.
Two people with the same chronological age can show different levels of frailty, metabolic health, vascular function, immune function, cognition, and disease risk.
A single person may also show different aging rates across the brain, heart, liver, kidneys, immune system, or musculoskeletal system.
Research note: Recent reviews describe the evolution of biological clocks from whole-body estimates toward organ-specific aging measurements using omics, clinical data, and imaging.
How precision aging is measured
Epigenetic clocks
These tools analyze DNA methylation patterns at selected sites across the genome.
Early clocks were optimized to predict chronological age.
Newer clocks attempt to estimate mortality risk, disease vulnerability, physiological decline, or pace of aging.
Examples discussed in aging research include first-generation age-prediction clocks, mortality-oriented clocks, and pace-of-aging measures such as DunedinPACE.
Clinical biomarker composites
Standard blood and physiological measurements can be combined into scores intended to approximate phenotypic aging.
Common research variables include glucose regulation, lipids, inflammatory markers, kidney and liver indicators, blood pressure, and blood-cell measures.
These tools may be more accessible than specialized omics tests but can be influenced by temporary illness, medication, hydration, and laboratory variation.
Proteomic and metabolomic aging
Proteomics evaluates patterns among proteins circulating in blood or expressed in tissues.
Metabolomics evaluates small molecules produced by metabolism.
These layers can reveal biological processes that DNA sequence alone does not show because proteins and metabolites change with physiology, environment, disease, and treatment.
Transcriptomic and immune aging
Transcriptomic research examines patterns of gene expression.
Immune-aging studies may evaluate immune-cell populations, inflammatory signals, antibody responses, and other indicators of immunosenescence.
Imaging, digital, and functional biomarkers
Researchers may use brain imaging, retinal imaging, vascular measurements, body composition, gait speed, grip strength, sleep data, or wearable-device signals.
Functional measures are valuable because molecular changes do not always translate directly into better real-world performance.
How precision aging research is done
Researchers define the aging outcome or organ system they want to measure.
They collect baseline data, which may include clinical biomarkers, DNA methylation, proteins, metabolites, imaging, performance measures, and lifestyle information.
Algorithms are trained or applied to produce an age estimate, risk estimate, or pace-of-aging score.
The measurement is compared with chronological age, future health outcomes, disease states, or functional performance.
In intervention studies, the measurement is repeated to determine whether the biomarker changes over time.
Researchers assess whether a biomarker change corresponds with meaningful clinical or functional outcomes.
What precision aging research has found
Aging is heterogeneous. People and organ systems do not age at identical rates.
DNA methylation clocks and related measures can associate with disease risk, morbidity, mortality, and physiological decline, although performance varies by clock and population.
Cardiometabolic factors such as smoking, higher body mass index, elevated glucose, and poor blood-pressure profiles have been associated with faster epigenetic aging measures in recent longitudinal research.
Physical activity and healthier dietary patterns have been associated with slower aging trajectories in some studies.
Organ-specific clocks may reveal health risks that are not visible in a single whole-body age estimate.
Research note: Association is not causation. A clock may be a useful risk marker without being the biological mechanism that causes aging.
Limitations of precision aging
Different clocks can provide different age estimates for the same person.
Some tools are trained on limited populations and may not perform equally across ancestry, sex, age, geography, or health status.
Short-term movement in a clock does not necessarily prove durable rejuvenation.
Commercial biological-age tests may not have the same validation as research-grade tools.
Researchers need repeated measurements, standardized sample handling, validated endpoints, and links to meaningful outcomes.
How precision aging could improve peptide research
Select participants according to biological features rather than chronological age alone.
Identify whether a peptide affects mitochondrial, immune, inflammatory, metabolic, or tissue-specific aging signatures.
Measure response heterogeneity instead of reporting only group averages.
Distinguish a temporary biomarker shift from a sustained functional benefit.
Develop organ-specific or pathway-specific endpoints for future clinical research.
Mitochondrial Optimization
Mitochondrial optimization is a research concept focused on preserving or improving mitochondrial quality, efficiency, adaptability, signaling, and turnover. The goal is not simply to maximize energy production. Healthy mitochondria must generate sufficient ATP, respond to changing energy demands, communicate with the nucleus, regulate calcium, manage stress, and remove damaged components without triggering excessive inflammation or cell death.
Why mitochondria matter in aging
Mitochondria generate much of the ATP required for cellular work.
They participate in nutrient sensing, redox signaling, calcium balance, innate immunity, apoptosis, and metabolic regulation.
Mitochondria contain their own DNA, which can accumulate damage and mutations over time.
Damaged mitochondria can produce altered reactive oxygen species signals and may release molecules that activate inflammatory pathways.
Mitochondrial decline has been associated with metabolic, cardiovascular, neurodegenerative, muscular, and other age-related disorders.
What scientists mean by optimization
Mitochondrial biogenesis
Biogenesis is the production of new mitochondrial components and, ultimately, new functional mitochondrial capacity.
Research frequently examines PGC-1alpha, AMPK, sirtuins, and related transcriptional regulators.
Biogenesis must be coordinated with removal of damaged mitochondria. Producing more mitochondria without quality control is not automatically beneficial.
Mitophagy
Mitophagy is the selective removal of damaged or dysfunctional mitochondria through autophagy-related machinery.
Researchers examine pathways such as PINK1 and Parkin, along with receptor-mediated mitophagy pathways.
Insufficient mitophagy may permit damaged mitochondria to accumulate.
Excessive or poorly regulated mitophagy may also impair cellular energy capacity, which is why balance matters.
Fusion and fission
Fusion allows mitochondrial contents to mix and can support functional complementation.
Fission divides mitochondria and can help isolate damaged segments for removal.
Age-related disruption of these dynamics may impair energy distribution and quality control.
Proteostasis and the mitochondrial stress response
Mitochondria require systems to fold proteins, remove damaged proteins, and respond to disrupted protein balance.
The mitochondrial unfolded protein response is studied as an adaptive stress pathway.
Mild stress can sometimes trigger protective adaptation, a concept called mitohormesis. More stress is not necessarily better.
Membrane integrity and cardiolipin biology
The inner mitochondrial membrane houses the electron transport chain.
Cardiolipin is a specialized membrane lipid important to mitochondrial architecture and respiratory complexes.
SS-31 research is closely associated with mitochondrial membrane and cardiolipin-related biology.
Redox balance
Reactive oxygen species are not solely harmful waste. At controlled levels they function as signals.
The research target is balanced redox signaling, not complete elimination of reactive oxygen species.
Mitochondrial communication
Retrograde signaling transmits information from mitochondria to the nucleus.
Mitochondrial-derived peptides such as MOTS-c and Humanin are studied as possible mediators of cellular and systemic communication.
How mitochondrial optimization is studied
ATP production and respiratory capacity
Oxygen-consumption and extracellular-acidification measurements
Mitochondrial membrane potential
Electron-transport-chain activity
Mitochondrial DNA copy number, mutations, and damage
Markers of mitophagy, biogenesis, fusion, and fission
Reactive oxygen species and antioxidant responses
Cell survival under metabolic or oxidative stress
Tissue-specific outcomes such as muscle endurance, cardiac function, retinal measures, or metabolic control
What mitochondrial research has found
Mitochondrial dysfunction is consistently associated with aging and multiple age-related disorders.
Quality-control processes, including mitophagy, dynamics, proteostasis, and mitochondrial-derived vesicles, are interconnected and must remain balanced.
Both overactivation and inhibition of quality-control pathways can be harmful in some contexts.
Mitochondrial-targeting interventions often show compelling effects in cells or animals, but translation to humans depends on disease, tissue, endpoint, delivery, and duration.
Mitochondrial function cannot be reduced to a single measurement. Improved ATP in one setting does not necessarily mean improved healthspan.
Research note: Reviews of mitochondrial quality control emphasize that balanced regulation is essential. A strategy that helps one tissue or disease model may not produce the same result elsewhere.
Peptides central to mitochondrial research
MOTS-c: studied for metabolic stress signaling, AMPK-related pathways, and mitochondrial-to-nuclear communication.
Humanin: studied for survival signaling, stress resistance, and mitochondrial communication.
SS-31: studied for mitochondrial membrane biology, cardiolipin interactions, and bioenergetic function.
SHLPs: small Humanin-like peptides investigated as members of the broader mitochondrial-derived peptide family.
Cellular Senescence Targeting
Cellular senescence is a durable state in which a cell stops dividing in response to stress or damage but remains metabolically active. Senescence can be beneficial when it helps prevent damaged cells from proliferating, supports selected wound-healing processes, or contributes to developmental biology. Problems may arise when senescent cells persist, accumulate, and alter surrounding tissue through inflammatory and remodeling signals.
What can cause a cell to become senescent
Telomere shortening
DNA damage
Oncogene activation
Oxidative stress
Mitochondrial dysfunction
Radiation or selected drug exposures
Chronic inflammatory or metabolic stress
Tissue injury and repeated cell replication
How senescent cells are identified
There is no single universal marker that identifies every senescent cell. Researchers commonly use a panel of features because senescence differs by cell type, trigger, tissue, and time.
Stable cell-cycle arrest
Changes in p16, p21, p53, or related pathways
Senescence-associated beta-galactosidase activity
Persistent DNA-damage signals
Altered cell shape, lysosomal content, and metabolism
Loss of proliferation markers
Senescence-associated secretory phenotype factors
The senescence-associated secretory phenotype
Many senescent cells release a changing mixture of cytokines, chemokines, growth factors, proteases, extracellular-matrix modifiers, and other signaling molecules. This profile is called the senescence-associated secretory phenotype, or SASP.
The SASP can recruit immune cells and assist temporary tissue repair.
Persistent SASP signaling may support chronic inflammation, fibrosis, impaired regeneration, and altered behavior in nearby cells.
The SASP is heterogeneous. Its composition depends on the cell, tissue, senescence trigger, and stage of the response.
Because senescence can be protective, indiscriminate removal of all senescent cells could be harmful.
How senescence is targeted
Senolytics
Senolytics are compounds designed to selectively trigger death in senescent cells by exploiting survival pathways on which those cells have become unusually dependent.
Research classes include inhibitors of selected BCL-2 family proteins, tyrosine-kinase-related strategies, and experimental peptide approaches.
The goal is selective removal, but selectivity differs among cell types and tissues.
Intermittent treatment concepts are sometimes studied because the objective is cell clearance rather than continuous pathway suppression. This remains protocol-specific research, not general-use guidance.
Senomorphics and senostatics
Senomorphics aim to suppress harmful features of senescent cells, particularly SASP signaling, without killing the cells.
Investigated pathways include mTOR, JAK-STAT, NF-kappaB, and other inflammatory or stress-response networks.
This approach may preserve beneficial cell-cycle arrest while reducing damaging secretions, although durable effects and tissue specificity remain research questions.
Immune-mediated clearance
Healthy immune systems can identify and remove some senescent cells.
Researchers are investigating vaccines, antibodies, engineered immune cells, and ways to restore natural immune surveillance.
A central challenge is identifying surface markers that distinguish harmful senescent cells from healthy cells.
Targeted delivery and prodrug strategies
Experimental approaches attempt to activate a compound only in senescent cells or deliver it to specific tissues.
Targeted delivery may reduce off-target toxicity, but it depends on reliable markers and delivery systems.
Reprogramming and regenerative strategies
Some research examines whether selected features of cellular age can be reset without erasing cell identity or promoting uncontrolled growth.
This field is distinct from senolytic research but may eventually be combined with cell-clearance or tissue-regeneration strategies.
How senescence-targeting studies are done
Researchers induce or identify senescence in cultured cells, animals, tissue samples, or defined patient populations.
A panel of senescence markers is used rather than relying on a single marker.
The intervention is tested for selective effects on senescent versus non-senescent cells.
Investigators measure SASP factors, inflammation, tissue structure, function, and adverse effects.
Animal studies may examine frailty, physical performance, metabolic function, fibrosis, or disease-specific outcomes.
Human trials must determine safety, pharmacology, target engagement, biomarker response, and clinically meaningful function.
What senescence research has found
Persistent senescent-cell accumulation is associated with aging and multiple age-related diseases.
Animal studies show that genetic or pharmacological reduction of selected senescent-cell populations can improve certain tissue and functional outcomes in specific models.
Early human studies have established feasibility for investigating senescence-targeting strategies in selected conditions, but evidence is not sufficient to claim generalized human age reversal.
Senolytics and senomorphics may have different advantages, risks, and ideal applications.
Senescent cells are diverse. A compound that targets one senescent-cell type may not affect another.
Researchers still need validated biomarkers that show whether harmful senescent cells were actually reduced in the intended tissue.
FOXO4-DRI and peptide-based senescence research
FOXO4-DRI is designed to disrupt a protein interaction involving FOXO4 and p53 in selected senescent cells.
The research concept is to weaken a survival mechanism and encourage apoptosis in susceptible senescent cells.
Published attention largely comes from preclinical work.
Major unanswered questions include delivery, selectivity, durability, tissue differences, immune effects, and long-term safety.
Why senescence targeting is difficult
Senescence is not one uniform cell state.
Temporary senescence can support wound healing and tumor suppression.
Markers shared with senescent cells may also appear in healthy or activated cells.
Removing too many cells could impair tissue integrity or regeneration.
Suppressing inflammatory signals could alter immune surveillance.
Short-term biomarker changes do not automatically prove slower aging or longer healthspan.
How the Three Research Pillars Connect
Precision aging asks what is changing
Biological clocks, organ-specific measurements, omics, imaging, and functional tests identify patterns of accelerated or resilient aging.
Mitochondrial optimization asks how cellular energy and stress systems are changing
Researchers measure bioenergetics, quality control, redox balance, mitophagy, dynamics, and mitochondrial signaling.
Senescence targeting asks what to do with persistently damaged or dysfunctional cells
Scientists investigate selective clearance, SASP modulation, immune surveillance, targeted delivery, and regeneration.
Why integration matters
Mitochondrial dysfunction can promote cellular senescence.
Senescent-cell signaling can impair mitochondrial function in surrounding tissue.
Precision-aging biomarkers may help identify which pathway is most abnormal and whether an intervention produces meaningful change.
Future studies may combine pathway-specific interventions with biomarker-guided participant selection and organ-specific outcomes.
The Future of Longevity Peptide Research
Better biomarkers: validated measurements that connect molecular change with real functional outcomes.
Organ-specific analysis: recognition that the brain, immune system, vasculature, liver, and muscle may age at different rates.
Stronger trial design: randomized studies with sufficient duration, transparent endpoints, and appropriate comparison groups.
Multi-omics integration: combining genomics, epigenomics, transcriptomics, proteomics, metabolomics, and clinical data.
Targeted delivery: placing an intervention in the relevant tissue while limiting off-target exposure.
Combination research: studying how mitochondrial, inflammatory, immune, senescence, and regenerative pathways interact.
Clear regulatory positioning: distinguishing approved medicines, investigational drugs, laboratory reagents, cosmetics, and research-use-only compounds.
Questions Researchers Should Ask When Evaluating a Longevity Peptide
What is the exact peptide sequence and molecular identity?
Is the evidence derived from cells, animals, observational human studies, or controlled clinical trials?
Was the peptide evaluated for a specific disease or for generalized aging?
What biomarkers were measured, and are they validated?
Were functional outcomes measured in addition to molecular markers?
Was the study replicated by independent researchers?
How was identity, purity, and quantity verified?
Were appropriate controls, blinding, and randomization used?
Are effects durable, tissue-specific, and biologically meaningful?
What adverse effects, off-target effects, or long-term uncertainties were reported?
Quality Documentation in Longevity Peptide Research
Scientific interpretation depends on knowing what material was actually tested. A purity percentage alone does not confirm identity, quantity, sterility, endotoxin status, or suitability for a particular experiment.
Mass spectrometry can support molecular identity.
High-performance liquid chromatography can characterize purity and related components.
Batch-specific documentation improves traceability.
Independent analytical testing can provide additional verification when the report is authentic and linked to the tested batch.
Researchers should compare the report identifier, sample name, batch information, test date, analytical methods, and verification link.
Research designs should document storage, handling, reconstitution method where applicable to the experiment, and stability conditions without converting research information into human-use instructions.
Final Perspective
The best longevity peptides being studied are not a single ranked list of proven anti-aging products. They are a diverse group of research tools connected to different biological questions.
MOTS-c and Humanin help researchers explore mitochondrial-derived signaling.
SS-31 helps investigate mitochondrial membrane and bioenergetic biology.
Epitalon remains associated with telomere, circadian, and cellular-aging hypotheses.
GHK-Cu is relevant to tissue remodeling and repair-oriented biology.
Thymosin Alpha-1 connects longevity research with immune aging and inflammatory balance.
FOXO4-DRI represents an experimental peptide approach to selected senescent-cell survival pathways.
KPV contributes to research on inflammatory signaling and epithelial barrier biology.
The most credible future studies will combine careful molecular characterization, validated biological-age measurements, mitochondrial and senescence biomarkers, meaningful functional outcomes, and transparent reporting. Until then, scientific interest should be communicated with precision: promising mechanisms are not the same as proven human longevity benefits.
Please visit the following for more research information:
